Research graph
References from Case Report: Mature tertiary lymphoid structures in a metastatic urothelial carcinoma patient with an exceptional response to sequential immune checkpoint inhibitor and antibody-drug conjugate therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
10.1056/nejmoa1613683 · 2017 · External reference
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · 2021 · External reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · 2024 · External reference
ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma
10.1016/j.annonc.2024.03.001 · 2024 · External reference
Tertiary lymphoid structures in the era of cancer immunotherapy
10.1038/s41568-019-0144-6 · 2019 · External reference
Tertiary lymphoid structures in anticancer immunity
10.1038/s41568-024-00728-0 · 2024 · External reference
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
10.1016/j.immuni.2023.08.009 · 2023 · External reference
Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis
10.3389/fimmu.2024.1385802 · 2024 · External reference
Quantitative image analysis for tissue biomarker use: A white paper from the Digital Pathology Association
10.1097/pai.0000000000000930 · 2021 · External reference
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
10.1136/jitc-2024-008875 · 2025 · External reference
A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment
10.1002/1878-0261.12764 · 2020 · External reference
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis
10.3389/fimmu.2024.1414884 · 2024 · External reference
Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer
10.1080/2162402x.2021.1915574 · 2021 · External reference
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab
10.1111/cas.15976 · 2023 · External reference
Tertiary lymphoid structures as independent predictors of favorable prognosis in muscle-invasive bladder cancer
10.1002/cam4.70978 · 2025 · External reference
Tertiary lymphoid structures are linked to enhanced antitumor immunity and better prognosis in muscle-invasive bladder cancer
10.1002/advs.202410998 · 2025 · External reference
Combining antibody-drug conjugates with immune checkpoint inhibitors in solid tumors: rationale and clinical progress
10.1016/j.annonc.2021.12.014 · 2022 · External reference
Antibody drug conjugate: the "biological missile" for targeted cancer therapy
10.1038/s41392-022-00947-7 · 2022 · External reference
Immune checkpoint inhibitors and antibody-drug conjugates in urothelial carcinoma: current landscape and future directions
10.3390/cancers17091594 · 2025 · External reference
Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method
10.1016/j.urolonc.2024.06.010 · 2024 · External reference
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
10.1056/nejmoa2002788 · 2020 · External reference
